WO2019008554A1 - Method for the oral treatment and prevention of cardiovascular disease - Google Patents

Method for the oral treatment and prevention of cardiovascular disease Download PDF

Info

Publication number
WO2019008554A1
WO2019008554A1 PCT/IB2018/055021 IB2018055021W WO2019008554A1 WO 2019008554 A1 WO2019008554 A1 WO 2019008554A1 IB 2018055021 W IB2018055021 W IB 2018055021W WO 2019008554 A1 WO2019008554 A1 WO 2019008554A1
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
cardiovascular disease
oral treatment
pharmaceutical product
growth hormone
Prior art date
Application number
PCT/IB2018/055021
Other languages
French (fr)
Inventor
Anthony CONTE
Original Assignee
Conte Anthony
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conte Anthony filed Critical Conte Anthony
Publication of WO2019008554A1 publication Critical patent/WO2019008554A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates generally to treatment and prevention of cardiovascular disease. More specifically, the present invention relates to the oral administration of non-petidyl growth hormone secretatoques for the treatment, reversal, and prevention of atherosclerosis, hypercholesterolemia, and related cardiovascular diseases.
  • Atherosclerosis is a blood vessel disease developing preferentially in subjects presenting substantial risks factors including poor diet, sedentary lifestyles, smoking, hypertension, diabetes mellitus, hypercholesterolemia, elevated plasma low-density lipoprotein (LDL) and triglycerides, hyperfibrinogenemia and hyperglycemia, among others.
  • Atherosclerotic lesions develop over a number of years and even decades in humans, leading to complications, such as coronary and cerebral ischemic and thromboembolic diseases and myocardial and cerebral infarction.
  • cardiovascular disease is the leading cause of morbidity and mortality in industrialized countries and progresses steadily in emerging countries, with coronary atherosclerosis being the main underlying pathology.
  • Atherosclerosis develops through the sequential interplay of at least three pathological processes: foam cell differentiation, inflammatory reaction and cell proliferation.
  • foam cell differentiation In human and a plurality of animal models, one of the earliest detectable events in the first of these processes is the recruitment of mononuclear phagocytes and
  • lymphocytes to the intact endothelial lining of large arteries.
  • Enhanced adhesion and accumulation of blood monocytes into the intima is then accompanied by a change in cell phenotype, where the blood monocytes transform into macrophages.
  • the latter engulfs lipids and stores them as cytoplasmic droplets, thus becoming “foam cells”.
  • the formation of said foam cells is a key stage in the development of early fatty streak lesions, and hence is a central event in atherogenesis.
  • GHRPs Growth hormone releasing peptides
  • hexarelin a hexapeptide member of the GHRP family, binds to a glycosylated membrane protein of 84 kilodaltons (kD) distinct from the Ghrelin receptor (see Circ. Res. 85, 796 (1999)). This protein was later identified as the cluster of differentiation 36 (CD36) receptor (see Circ. Res. 90, 844 (2002)).
  • mice selected and breed ApoE-null mice as an experimental model of atherosclerosis as it features the progressive series of atherogenic events seen in humans, including increased adhesive interactions between leukocyte and endothelium, conversion of monocyte-derived macrophages into foam cells with lesions distributing throughout the arterial tree, and late development of more advanced lesions (fibrous plaques).
  • ApoE-null mice show very high levels of plasma cholesterol as a result of impaired clearance of cholesterol-enriched lipoproteins and, as for humans, high cholesterol high fat (HCHF) diet exacerbates disease progression and markedly enhances plasma cholesterol levels (see J. Clin. Invest. 105(8), 1049-1056 (2000) and J. Clin. Invest. 105, 1039-1041 (2000)).
  • Evidence accumulates to support that fatty streaks in anatomical sites prone to athermanous plaque development precede mature lesions in humans, although all fatty streaks do not progress to atheromas (see Arterioscler.
  • T lymphocyte and foam cells are found in fatty streaks and immunological processes have been shown to be similar over the years in both species.
  • GHRPs reduce total plasma cholesterol and cholesterol that is not high-density lipoprotein (HDL) cholesterol, and increase HDL cholesterol in ApoE-deficient mice fed with a HFHC diet from six weeks old. These favorable changes in plasma lipids were associated with a significant decrease in fatty streak lesion area in the ApoE-null mice treated with GHRPs, as compared with controls.
  • HDL high-density lipoprotein
  • the present inventor further theorizes that arterial plaque and fatty streaks that were reversed and reduced through the administration of growth hormone releasing peptides (GHRPs) in the ApoE-deficient mice was facilitated by growth hormone- releasing activity of the GHRPs.
  • the present inventor further believes that the same results can be achieved by the oral administration of ibutamoren mesylate, capromorelin, tabimorelin, and/or similar non-peptidyl small molecule growth hormone releasing agents.
  • the present inventor believes and theorizes that enhanced levels of growth hormone that result from GHRPs injection administration and oral administration of ibutamoren mesylate, capromorelin, tabimorelin, and/or similar non-peptidyl small molecule growth hormone releasing agents enhance and improve Nitric Oxide (NO) levels in the endothelial lining of arteries leading to the reduction of arterial plaque and fatty streak lesions.
  • the present inventor further believes and theorizes that enhanced levels of growth hormone achieve these results by directly controlling, regulating and suppressing over production of the stress hormone Cortisol which is a known atherogenic causing agent.
  • FIG. 1 is a flow diagram for the general process of the present invention.
  • FIG. 2 is a flow diagram for a specific embodiment of the present invention.
  • FIG. 3 is a flow diagram for a specific embodiment of the present invention.
  • FIG. 4 is an ingredient list for the quantity of non-peptidyl growth hormone secretatoques of the present invention.
  • FIG. 5 is an ingredient list for the quantity of adjuvants of the present invention.
  • FIG. 6 is an ingredient list for the quantity of carrier agents of the present invention.
  • FIG. 7 is an ingredient list for the quantity of blood lipid lowering agents of the present invention.
  • FIG. 8 is an ingredient list for the quantity of additional additives of the present invention.
  • the present invention is a method for the oral treatment and prevention of cardiovascular disease.
  • Cardiovascular disease associated with atherosclerotic processes are medically linked to atherosclerosis and are a consequence of atherosclerotic lesions.
  • Cardiovascular diseases associated with atherosclerosis include coronary artery disease, myocardial infarction and strokes.
  • the present invention improves upon prior art to reduce uptake of oxidized low-density lipoprotein (oxLDL), reduce the accumulation of lipids and cholesterol, and reduce the formation of fatty streak lesions.
  • oxLDL oxidized low-density lipoprotein
  • Patients who would benefit from the present invention include, but are not limited to: patients having coronary heart disease; patients at risk of developing coronary heart disease due to a plurality of risk factors, such as obesity, smoking, hypertension, diabetes, mellitus, and a family history of premature coronary heart disease; patients with familial conditions characterized by very high plasma concentrations of cholesterol and/or triglycerides; patients with hyperlipidemia not secondary to underlying diseases, such as hypothyroidism, nephrotic syndrome, hepatic disease, or alcoholism; patients with elevated LDL-cholesterol; or patients with hypolipidemic intervention.
  • risk factors such as obesity, smoking, hypertension, diabetes, mellitus, and a family history of premature coronary heart disease
  • patients with familial conditions characterized by very high plasma concentrations of cholesterol and/or triglycerides patients with hyperlipidemia not secondary to underlying diseases, such as hypothyroidism, nephrotic syndrome, hepatic disease, or alcoholism
  • Step A a quantity of non-peptidyl growth hormone secretatoques, a quantity of adjuvants, a quantity of diluents, and a quantity of carrier agents are required (Step A), shown in FIG. 1.
  • the quantity of non-peptidyl growth hormone secretatoques is a small molecule secretatoque that facilitates the secretion of growth hormones.
  • secretatoques binds to the same receptors as growth hormone releasing peptides (GHRPs) to reduce the uptake of oxLDL, to reduce the accumulation of lipids and cholesterol, and to reduce the formation of fatty streak lesions.
  • GHRPs growth hormone releasing peptides
  • the quantity of adjuvants, the quantity of diluents, and the quantity of carriers allow for the quantity of non-peptidyl growth hormone secretatoques to be delivered more effectively to the patient.
  • the quantity of the quantity of non-peptidyl growth hormone secretatoques, the quantity of adjuvants, the quantity of diluents, and the quantity of carrier agents are mixed into a pharmaceutical product that is administrable to a patient (Step B). Subsequently, the pharmaceutical product is orally administered to the patient (Step C), such that the pharmaceutical product is able to be metabolized by the patient.
  • the pharmaceutical product is preferred to be administered twice daily, detailed in FIG. 2. For an alternate embodiment of the present invention, the pharmaceutical product is administered once daily, detailed in FIG. 3.
  • the quantity of non-peptidyl growth hormone secretatoques is selected from the group consisting of ibutamoren mesylate, capromorelin, tabimorelin, or combinations thereof, shown in FIG. 4.
  • the quantity of non-peptidyl growth hormone secretatoques is preferred to be a combination of a quantity of ibutamoren mesylate, a quantity of capromorelin, and a quantity of tabimorelin, as these compounds mimic the receptor binding activities of GHRPs.
  • the pharmaceutical product comprises the quantity of ibutamoren mesylate, the quantity of ibutamoren mesylate is between 10 milligrams (mg) and 25 mg.
  • the pharmaceutical product is administered twice a day and the quantity of non-peptidyl growth hormone secretatoques comprises the quantity of ibutamoren mesylate
  • the quantity of ibutamoren mesylate is preferred to be approximately lOmg, shown in FIG. 2.
  • the pharmaceutical product is administered once a day and the quantity of non-peptidyl growth hormone secretatoques comprises the quantity of ibutamoren mesylate
  • the quantity of ibutamoren mesylate is preferred to be approximately 25mg, shown in FIG. 3.
  • the quantity of non-peptidyl growth hormone secretatoques enhances and improve nitric oxide (NO) levels in the endothelial lining of arteries leading to the reduction of arterial plaque and fatty streak lesions.
  • NO nitric oxide
  • the quantity of non-peptidyl growth hormone secretatoques assists in preventing the development of and/or treating atherosclerotic plaques and cardiovascular disease.
  • the quantity of non-peptidyl growth hormone secretatoques is less expensive to manufacture, less perishable, and easier to receive dosages in comparison to daily injections of GHRPs.
  • the quantity of adjuvants is selected from the group consisting of stearic acid, glycerin, magnesium stearate, silicon dioxide, and
  • Steric acid, glycerin, magnesium stearate, and silicon dioxide assist the delivery of the quantity of non-peptidyl growth hormone secretatoques to the recipient of the pharmaceutical product.
  • the quantity of diluents dilutes the
  • the quantity of diluent is preferred to be lanolin, as lanolin is a solvent for active ingredients of the pharmaceutical product, detailed in FIG. 2.
  • the quantity of carrier agents imparts favorable transport properties to the pharmaceutical product.
  • the quantity of carrier agents is selected from the group consisting of magnesium stearate, stearic acid, carrageenan, silicon dioxide, glycerin, and combinations thereof, in accordance to FIG. 6. Magnesium stearate, stearic acid, and silicon dioxide are flow agents to prevent the active ingredients from caking such that the active ingredients are easier to metabolize.
  • the carrageenan is a thickening agent to modify the viscosity of the active ingredients.
  • a binding agent is used to hold the pharmaceutical product together, detailed in FIG. 2.
  • the pharmaceutical product is cohered with the pharmaceutical product to encapsulate and consolidate the
  • the binding agent is preferred to be gelatin, as gelatin is an effective compound to stabilize and secure the ingredients of the
  • a quantity of blood lipid lowering agents is pharmaceutically active compounds utilized to lower total cholesterol, triglyceride levels, low-density lipoprotein, and (LDL) cholesterol levels within the patient's blood and increase the levels of high-density lipoprotein (HDL) cholesterol in the patient's blood.
  • the quantity of blood lipid lowering agents are mixed into the pharmaceutical product to be simultaneously imbibed by the patient, during Step B, shown in FIG. 2 and FIG. 3. In accordance to FIG.
  • the quantity of blood lipid lower agents is selected from the group consisting of statins, fibrates, bile-acid binding resins, nicotinates, omega-3-triglycerides, acyl-coenzyme A acetyltransferases (ACAT) inhibitors, peroxisome proliferator- activated receptor gamma (PPARG) agonists, cholesterol absorption inhibitors, lipase inhibitors, and combinations thereof.
  • statins statins
  • fibrates bile-acid binding resins
  • nicotinates nicotinates
  • omega-3-triglycerides acyl-coenzyme A acetyltransferases (ACAT) inhibitors
  • PARG peroxisome proliferator- activated receptor gamma
  • HMG-CoA 3-hydroxy-3-methylglutaral-coenzyme A reductase
  • atorvastatin cerivastatin
  • fluvastatin fluvastatin
  • lovastatin mevastatin
  • pravastatin rosuvastatin
  • simvastatin simvastatin
  • Fibrates include, but are not limited to, beclobrate, bezafibrate, ciprofibrate, clinofibrate, clofibrate, clofibride, etofylline clofibrate, fenofibrate, gemfibrozil, pirifibrate, plafibride, simfibrate, tocofibrate, and other derivatives of fibric acid.
  • Bile-acid binding resins include but are not limited to colesevelam, colestipol, colestyr amine, and divistyramine.
  • Nicotinates include, but are not limited to, acipimox, binifibrate, etofibrate, niceritrol, nicofibrate, pirozadil, ronifibrate, sorbinicate, tocoferil nicotinate, nicotinic acids, and derivatives of nicotinic acid.
  • Omega-3-tryglicerides include, but are not limited to, omega-3-acid ethyl esters and omega-3-marine triglycerides.
  • ACAT inhibitors include, but are not limited to, avasimibe.
  • PPARG agonists include, but are not limited to, pioglitazone.
  • Lipase inhibitors include, but are not limited to, orlistat.
  • the quantity of blood lipid lowering agents is approximately 50 percent by weight (wt%) to 90 wt% of the pharmaceutical product in order to provide an effective dosage for the quantity of blood lipid lowering agents to the patient.
  • a quantity of additional additives is included to further manipulate the physical properties of the pharmaceutical product.
  • the quantity of additional additives is mixed into the pharmaceutical product.
  • the quantity of additional additives is selected from the group consisting of titanium dioxide, glycerin, and combinations thereof, shown in FIG. 8. Titanium dioxide colors the pharmaceutical product white. Glycerin is a preservative that extends the duration before the pharmaceutical product becomes less effective, and glycerin is also a sweetener to make the consumption of the pharmaceutical product more palatable to the patient.
  • the present invention is able to be applied to patients for the treatment or prophylaxis of coronary cardiovascular diseases, for the treatment of prophylaxis of atherosclerosis or hypercholesterolemia, for increasing expression of genes involved in cellular cholesterol efflux, or for reducing the total blood plasma cholesterol level.

Abstract

A method for the oral treatment and prevention of cardiovascular disease utilizes a quantity of non-peptidyl growth hormone secretagogues for: the prophylaxis of atherosclerosis and hypercholesterolemia, preventing the development atherosclerotic plaques and cardiovascular disease; the treatment of pre-existing atherosclerosis or hypercholesterolemia; the reduction of total blood plasma cholesterol levels in a patient's blood; and the expression of genes involved in cellular cholesterol efflux. The quantity of non-peptidyl growth hormone secretagogues is orally administered to the patient. The quantity of non-peptidyl growth hormone secretagogues is selected from the group consisting of ibutamoren mesylate, capromorelin, tabimorelin, and combinations thereof.

Description

Method for the Oral Treatment and Prevention of Cardiovascular
Disease
The current application claims a priority to the U.S. Provisional Patent application serial number 62/529,257 filed on July 6, 2017.
FIELD OF THE INVENTION The present invention relates generally to treatment and prevention of cardiovascular disease. More specifically, the present invention relates to the oral administration of non-petidyl growth hormone secretatoques for the treatment, reversal, and prevention of atherosclerosis, hypercholesterolemia, and related cardiovascular diseases.
BACKGROUND OF THE INVENTION
Atherosclerosis is a blood vessel disease developing preferentially in subjects presenting substantial risks factors including poor diet, sedentary lifestyles, smoking, hypertension, diabetes mellitus, hypercholesterolemia, elevated plasma low-density lipoprotein (LDL) and triglycerides, hyperfibrinogenemia and hyperglycemia, among others. Atherosclerotic lesions develop over a number of years and even decades in humans, leading to complications, such as coronary and cerebral ischemic and thromboembolic diseases and myocardial and cerebral infarction. To date, cardiovascular disease is the leading cause of morbidity and mortality in industrialized countries and progresses steadily in emerging countries, with coronary atherosclerosis being the main underlying pathology. Currently, therapy of atherosclerosis is not completely efficient to prevent and reverse disease development and complication. Atherosclerosis develops through the sequential interplay of at least three pathological processes: foam cell differentiation, inflammatory reaction and cell proliferation. In human and a plurality of animal models, one of the earliest detectable events in the first of these processes is the recruitment of mononuclear phagocytes and
lymphocytes to the intact endothelial lining of large arteries. Enhanced adhesion and accumulation of blood monocytes into the intima is then accompanied by a change in cell phenotype, where the blood monocytes transform into macrophages. The latter engulfs lipids and stores them as cytoplasmic droplets, thus becoming "foam cells". The formation of said foam cells is a key stage in the development of early fatty streak lesions, and hence is a central event in atherogenesis.
Growth hormone releasing peptides (GHRPs), which consist of a family of small synthetic peptides modeled from Met-enkephalin, possess potent and dose dependent growth hormone- releasing activity and significant prolactin and corticotropin-releasing effects (see Horm. Res. 51(suppl. 3), 9 (1999)).
A study of GHRP binding sites in the cardiovascular system found that hexarelin, a hexapeptide member of the GHRP family, binds to a glycosylated membrane protein of 84 kilodaltons (kD) distinct from the Ghrelin receptor (see Circ. Res. 85, 796 (1999)). This protein was later identified as the cluster of differentiation 36 (CD36) receptor (see Circ. Res. 90, 844 (2002)).
Prior art suggests that a prolonged treatment, at leastl2 weeks, with GHRPs interferes with the CD36 scavenger receptor function and expression, thereby reducing the uptake of oxidized LDL (oxLDL) and the accumulation of lipids and cholesterol, and consequently, reducing the formation of fatty streak lesions in apolipoprotein E (ApoE) null mice (see United States Patent US 7785567 B2).
The authors of that patented invention selected and breed ApoE-null mice as an experimental model of atherosclerosis as it features the progressive series of atherogenic events seen in humans, including increased adhesive interactions between leukocyte and endothelium, conversion of monocyte-derived macrophages into foam cells with lesions distributing throughout the arterial tree, and late development of more advanced lesions (fibrous plaques).
Also, ApoE-null mice show very high levels of plasma cholesterol as a result of impaired clearance of cholesterol-enriched lipoproteins and, as for humans, high cholesterol high fat (HCHF) diet exacerbates disease progression and markedly enhances plasma cholesterol levels (see J. Clin. Invest. 105(8), 1049-1056 (2000) and J. Clin. Invest. 105, 1039-1041 (2000)). Evidence accumulates to support that fatty streaks in anatomical sites prone to athermanous plaque development precede mature lesions in humans, although all fatty streaks do not progress to atheromas (see Arterioscler.
Thromb. Vase. Biol. 19, 2364-2367 (1999)). In both human and mice, T lymphocyte and foam cells are found in fatty streaks and immunological processes have been shown to be similar over the years in both species.
The authors of this prior art found that GHRPs reduce total plasma cholesterol and cholesterol that is not high-density lipoprotein (HDL) cholesterol, and increase HDL cholesterol in ApoE-deficient mice fed with a HFHC diet from six weeks old. These favorable changes in plasma lipids were associated with a significant decrease in fatty streak lesion area in the ApoE-null mice treated with GHRPs, as compared with controls.
The present inventor further theorizes that arterial plaque and fatty streaks that were reversed and reduced through the administration of growth hormone releasing peptides (GHRPs) in the ApoE-deficient mice was facilitated by growth hormone- releasing activity of the GHRPs. The present inventor further believes that the same results can be achieved by the oral administration of ibutamoren mesylate, capromorelin, tabimorelin, and/or similar non-peptidyl small molecule growth hormone releasing agents.
The present inventor believes and theorizes that enhanced levels of growth hormone that result from GHRPs injection administration and oral administration of ibutamoren mesylate, capromorelin, tabimorelin, and/or similar non-peptidyl small molecule growth hormone releasing agents enhance and improve Nitric Oxide (NO) levels in the endothelial lining of arteries leading to the reduction of arterial plaque and fatty streak lesions. The present inventor further believes and theorizes that enhanced levels of growth hormone achieve these results by directly controlling, regulating and suppressing over production of the stress hormone Cortisol which is a known atherogenic causing agent.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a flow diagram for the general process of the present invention.
FIG. 2 is a flow diagram for a specific embodiment of the present invention.
FIG. 3 is a flow diagram for a specific embodiment of the present invention.
FIG. 4 is an ingredient list for the quantity of non-peptidyl growth hormone secretatoques of the present invention.
FIG. 5 is an ingredient list for the quantity of adjuvants of the present invention.
FIG. 6 is an ingredient list for the quantity of carrier agents of the present invention. FIG. 7 is an ingredient list for the quantity of blood lipid lowering agents of the present invention.
FIG. 8 is an ingredient list for the quantity of additional additives of the present invention.
DETAIL DESCRIPTIONS OF THE INVENTION
All illustrations of the drawings are for the purpose of describing selected versions of the present invention and are not intended to limit the scope of the present invention.
The present invention is a method for the oral treatment and prevention of cardiovascular disease. Cardiovascular disease associated with atherosclerotic processes are medically linked to atherosclerosis and are a consequence of atherosclerotic lesions. Cardiovascular diseases associated with atherosclerosis include coronary artery disease, myocardial infarction and strokes. The present invention improves upon prior art to reduce uptake of oxidized low-density lipoprotein (oxLDL), reduce the accumulation of lipids and cholesterol, and reduce the formation of fatty streak lesions.
Patients who would benefit from the present invention include, but are not limited to: patients having coronary heart disease; patients at risk of developing coronary heart disease due to a plurality of risk factors, such as obesity, smoking, hypertension, diabetes, mellitus, and a family history of premature coronary heart disease; patients with familial conditions characterized by very high plasma concentrations of cholesterol and/or triglycerides; patients with hyperlipidemia not secondary to underlying diseases, such as hypothyroidism, nephrotic syndrome, hepatic disease, or alcoholism; patients with elevated LDL-cholesterol; or patients with hypolipidemic intervention.
In order to execute the present invention, a quantity of non-peptidyl growth hormone secretatoques, a quantity of adjuvants, a quantity of diluents, and a quantity of carrier agents are required (Step A), shown in FIG. 1. The quantity of non-peptidyl growth hormone secretatoques is a small molecule secretatoque that facilitates the secretion of growth hormones. The quantity of non-peptidyl growth hormone
secretatoques binds to the same receptors as growth hormone releasing peptides (GHRPs) to reduce the uptake of oxLDL, to reduce the accumulation of lipids and cholesterol, and to reduce the formation of fatty streak lesions. The quantity of adjuvants, the quantity of diluents, and the quantity of carriers allow for the quantity of non-peptidyl growth hormone secretatoques to be delivered more effectively to the patient.
In accordance to FIG. 1, the quantity of the quantity of non-peptidyl growth hormone secretatoques, the quantity of adjuvants, the quantity of diluents, and the quantity of carrier agents are mixed into a pharmaceutical product that is administrable to a patient (Step B). Subsequently, the pharmaceutical product is orally administered to the patient (Step C), such that the pharmaceutical product is able to be metabolized by the patient. The pharmaceutical product is preferred to be administered twice daily, detailed in FIG. 2. For an alternate embodiment of the present invention, the pharmaceutical product is administered once daily, detailed in FIG. 3.
The quantity of non-peptidyl growth hormone secretatoques is selected from the group consisting of ibutamoren mesylate, capromorelin, tabimorelin, or combinations thereof, shown in FIG. 4. The quantity of non-peptidyl growth hormone secretatoques is preferred to be a combination of a quantity of ibutamoren mesylate, a quantity of capromorelin, and a quantity of tabimorelin, as these compounds mimic the receptor binding activities of GHRPs. Wherein the pharmaceutical product comprises the quantity of ibutamoren mesylate, the quantity of ibutamoren mesylate is between 10 milligrams (mg) and 25 mg. Wherein the pharmaceutical product is administered twice a day and the quantity of non-peptidyl growth hormone secretatoques comprises the quantity of ibutamoren mesylate, the quantity of ibutamoren mesylate is preferred to be approximately lOmg, shown in FIG. 2. Wherein the pharmaceutical product is administered once a day and the quantity of non-peptidyl growth hormone secretatoques comprises the quantity of ibutamoren mesylate, the quantity of ibutamoren mesylate is preferred to be approximately 25mg, shown in FIG. 3. The quantity of non-peptidyl growth hormone secretatoques enhances and improve nitric oxide (NO) levels in the endothelial lining of arteries leading to the reduction of arterial plaque and fatty streak lesions. The quantity of non-peptidyl growth hormone secretatoques assists in preventing the development of and/or treating atherosclerotic plaques and cardiovascular disease. The quantity of non-peptidyl growth hormone secretatoques is less expensive to manufacture, less perishable, and easier to receive dosages in comparison to daily injections of GHRPs.
In accordance to FIG. 5, the quantity of adjuvants is selected from the group consisting of stearic acid, glycerin, magnesium stearate, silicon dioxide, and
combinations thereof. Steric acid, glycerin, magnesium stearate, and silicon dioxide assist the delivery of the quantity of non-peptidyl growth hormone secretatoques to the recipient of the pharmaceutical product. The quantity of diluents dilutes the
pharmaceutical product such that the pharmaceutical product is easier to metabolize by the imbiber of the pharmaceutical compound. The quantity of diluent is preferred to be lanolin, as lanolin is a solvent for active ingredients of the pharmaceutical product, detailed in FIG. 2. The quantity of carrier agents imparts favorable transport properties to the pharmaceutical product. The quantity of carrier agents is selected from the group consisting of magnesium stearate, stearic acid, carrageenan, silicon dioxide, glycerin, and combinations thereof, in accordance to FIG. 6. Magnesium stearate, stearic acid, and silicon dioxide are flow agents to prevent the active ingredients from caking such that the active ingredients are easier to metabolize. The carrageenan is a thickening agent to modify the viscosity of the active ingredients.
In some embodiments of the present invention a binding agent is used to hold the pharmaceutical product together, detailed in FIG. 2. The pharmaceutical product is cohered with the pharmaceutical product to encapsulate and consolidate the
pharmaceutical product, after Step B. The binding agent is preferred to be gelatin, as gelatin is an effective compound to stabilize and secure the ingredients of the
pharmaceutical product together to be simultaneously imbibed by the patient.
In some embodiments of the present invention, a quantity of blood lipid lowering agents is pharmaceutically active compounds utilized to lower total cholesterol, triglyceride levels, low-density lipoprotein, and (LDL) cholesterol levels within the patient's blood and increase the levels of high-density lipoprotein (HDL) cholesterol in the patient's blood. The quantity of blood lipid lowering agents are mixed into the pharmaceutical product to be simultaneously imbibed by the patient, during Step B, shown in FIG. 2 and FIG. 3. In accordance to FIG. 7, the quantity of blood lipid lower agents is selected from the group consisting of statins, fibrates, bile-acid binding resins, nicotinates, omega-3-triglycerides, acyl-coenzyme A acetyltransferases (ACAT) inhibitors, peroxisome proliferator- activated receptor gamma (PPARG) agonists, cholesterol absorption inhibitors, lipase inhibitors, and combinations thereof. Statins inhibitors of 3-hydroxy-3-methylglutaral-coenzyme A (HMG-CoA) reductase that include, but are not limited to, atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pravastatin, rosuvastatin, and simvastatin. Fibrates include, but are not limited to, beclobrate, bezafibrate, ciprofibrate, clinofibrate, clofibrate, clofibride, etofylline clofibrate, fenofibrate, gemfibrozil, pirifibrate, plafibride, simfibrate, tocofibrate, and other derivatives of fibric acid. Bile-acid binding resins include but are not limited to colesevelam, colestipol, colestyr amine, and divistyramine. Nicotinates include, but are not limited to, acipimox, binifibrate, etofibrate, niceritrol, nicofibrate, pirozadil, ronifibrate, sorbinicate, tocoferil nicotinate, nicotinic acids, and derivatives of nicotinic acid. Omega-3-tryglicerides include, but are not limited to, omega-3-acid ethyl esters and omega-3-marine triglycerides. ACAT inhibitors include, but are not limited to, avasimibe. PPARG agonists include, but are not limited to, pioglitazone. Lipase inhibitors include, but are not limited to, orlistat. The quantity of blood lipid lowering agents is approximately 50 percent by weight (wt%) to 90 wt% of the pharmaceutical product in order to provide an effective dosage for the quantity of blood lipid lowering agents to the patient.
In some embodiments of the present invention, a quantity of additional additives is included to further manipulate the physical properties of the pharmaceutical product. During Step B, the quantity of additional additives is mixed into the pharmaceutical product. The quantity of additional additives is selected from the group consisting of titanium dioxide, glycerin, and combinations thereof, shown in FIG. 8. Titanium dioxide colors the pharmaceutical product white. Glycerin is a preservative that extends the duration before the pharmaceutical product becomes less effective, and glycerin is also a sweetener to make the consumption of the pharmaceutical product more palatable to the patient.
For implementation of the present invention, the present invention is able to be applied to patients for the treatment or prophylaxis of coronary cardiovascular diseases, for the treatment of prophylaxis of atherosclerosis or hypercholesterolemia, for increasing expression of genes involved in cellular cholesterol efflux, or for reducing the total blood plasma cholesterol level.
Although the invention has been explained in relation to its preferred
embodiment, it is to be understood that many other possible modifications and variations can be made without departing from the spirit and scope of the invention as hereinafter claimed.

Claims

What is claimed is:
1. A method for the oral treatment and prevention of cardiovascular disease
comprises the steps of:
(A) providing a quantity of non-peptidyl growth hormone secretatoques, a quantity of adjuvants, a quantity of diluents, and a quantity of carrier agents;
(B) mixing the quantity of non-peptidyl growth hormone secretatoques, the quantity of adjuvants, the quantity of diluents, and the quantity of carrier agents into a pharmaceutical product;
(C) orally administering the pharmaceutical product to a patient;
The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 1, comprises the step of:
administering the pharmaceutical product to the patient twice daily;
The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 1, comprises the step of:
administering the pharmaceutical product to the patient once daily;
The method for the oral treatment and prevention of cardiovascular disease, claimed in claim 1 , wherein the quantity of non-peptidyl growth hormone secretatoques is selected from the group consisting of ibutamoren mesylate, capromorelin, tabimorelin, and combinations thereof.
The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 4, comprises:
wherein the quantity of non-peptidyl growth hormone secretatoques comprises a quantity of ibutamoren mesylate;
the quantity of ibutamoren mesylate being between 10 milligrams (mg) and 25mg.
6. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 5, comprises:
wherein the pharmaceutical mixture is administered twice daily; the quantity of ibutamoren mesylate being approximately lOmg;
7. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 5, comprises:
wherein the pharmaceutical mixture is administered once daily; the quantity of ibutamoren mesylate being approximately 25mg;
8. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 1 , wherein the quantity of adjuvants is selected from the group consisting of stearic acid, glycerin, magnesium stearate, silicon dioxide, and combinations thereof.
9. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 1 , wherein the quantity of carrier agents is selected from a group consisting of magnesium stearate, stearic acid, carrageenan, silicon dioxide, glycerin, and combinations thereof.
10. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 1, wherein the quantity of diluents comprises lanolin.
11. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 1, comprises the steps of:
providing a quantity of blood lipid lowering agents;
mixing the quantity of blood lipid lowering agents into the pharmaceutical product, during Step B;
12. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 11 , wherein the quantity of blood lipid lowering agents is selected from the group consisting of statins, fibrates, bile-acid binding resins, nicotinates, omega-3-triglycerides, acyl-coenzyme A acetyltransferases (ACAT) inhibitors, peroxisome proliferator-activated receptor gamma (PPARG) agonists, cholesterol absorption inhibitors, lipase inhibitors, and combinations thereof.
13. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 11 , wherein the quantity of blood lipid lowering agents is approximately 50 percent by weight (wt%) to 90 wt% of the pharmaceutical product;
14. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 1, comprises the step of:
providing a binding agent;
cohering the pharmaceutical product with the binding agent, after Step B;
15. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 14, wherein the binding agent comprises gelatin.
16. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 1, comprises the steps of:
providing a quantity of additional additives;
mixing the quantity of additional additives into the pharmaceutical product, during Step B;
17. The method for the oral treatment and prevention of cardiovascular disease, as claimed in claim 16, wherein the quantity of additional additives is selected from the group consisting of titanium dioxide, glycerin, and combinations thereof.
PCT/IB2018/055021 2017-07-06 2018-07-06 Method for the oral treatment and prevention of cardiovascular disease WO2019008554A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762529257P 2017-07-06 2017-07-06
US62/529,257 2017-07-06

Publications (1)

Publication Number Publication Date
WO2019008554A1 true WO2019008554A1 (en) 2019-01-10

Family

ID=64950719

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/055021 WO2019008554A1 (en) 2017-07-06 2018-07-06 Method for the oral treatment and prevention of cardiovascular disease

Country Status (1)

Country Link
WO (1) WO2019008554A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210059993A1 (en) * 2018-02-14 2021-03-04 Lumos Pharma, Inc. Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
US20070219226A1 (en) * 2006-03-15 2007-09-20 Thorner Michael O Methods for treating sarcopenia with a growth hormone secretagogue
US7785567B2 (en) * 2002-08-23 2010-08-31 Valorisation-Recherche, Société en Commandite Growth hormone-releasing peptides in the treatment or prevention of atherosclerosis and hypercholesterolemia
US20140141076A1 (en) * 2011-09-02 2014-05-22 Fujifilm Corporation Soft capsule preparation, composition for soft capsule preparation, and method of producing soft capsule preparation
US20160243197A1 (en) * 2015-02-24 2016-08-25 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
US7785567B2 (en) * 2002-08-23 2010-08-31 Valorisation-Recherche, Société en Commandite Growth hormone-releasing peptides in the treatment or prevention of atherosclerosis and hypercholesterolemia
US20070219226A1 (en) * 2006-03-15 2007-09-20 Thorner Michael O Methods for treating sarcopenia with a growth hormone secretagogue
US20140141076A1 (en) * 2011-09-02 2014-05-22 Fujifilm Corporation Soft capsule preparation, composition for soft capsule preparation, and method of producing soft capsule preparation
US20160243197A1 (en) * 2015-02-24 2016-08-25 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PERLSTEIN, D ET AL.: "Oral Administration of Penicillin in Corn Oil and Lanolin", SCIENCE, vol. 102, no. 2638, 20 July 1945 (1945-07-20), pages 66 - 67, XP055564108 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210059993A1 (en) * 2018-02-14 2021-03-04 Lumos Pharma, Inc. Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Similar Documents

Publication Publication Date Title
JP5490409B2 (en) Preparations for the treatment of lipoprotein abnormalities comprising statins and methylnicotinamide derivatives
Karila et al. New treatments for cocaine dependence: a focused review
EP1353696B1 (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20030153541A1 (en) Novel anticholesterol compositions and method for using same
CN110025608A (en) The method for reducing risk of cardiovascular diseases
JP2001514222A (en) Therapeutic combinations containing amlodipine and atorvastatin
JP2001514224A (en) Combination therapy including amlodipine and statin compound
IL294736A (en) Compositions comprising 15-hepe and methods of using the same
US5426120A (en) Pharmaceutical composition containing γ-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders
Stein et al. Future directions to establish lipoprotein (a) as a treatment for atherosclerotic cardiovascular disease
JP2005539091A (en) Growth hormone releasing peptides in the treatment or prevention of atherosclerosis and hypercholesterolemia
US9034310B2 (en) Interferon-statin combination cancer therapy
US20180125816A1 (en) Saroglitazar magnesium for the treatment of chylomicronemia syndrome
WO2019008554A1 (en) Method for the oral treatment and prevention of cardiovascular disease
JP2017536380A (en) Compositions comprising 15-HEPE and methods for treating or preventing fibrosis using the same
US7199112B2 (en) Use of phospholipid arachidonic acids for increasing muscle mass in humans
CN1777417A (en) Use of a pparalpha agonist and metformin for decreasing the serum triglycerides
US6890941B1 (en) Compositions containing HMG Co-A reductase inhibitors and policosanol
US20030064932A1 (en) Methods of treatment comprising administration of Substance P
WO2020028124A1 (en) NEW USE OF CARBAMATE β PHENYLETHANOLAMINE ANALOGUES FOR ENHANCING INTRACELLULAR CLEARANCE OF LDL CHOLESTEROL AND FOR COMBINING THERAPY WITH STATINS TO ENHANCE THE EFFICACY AND REDUCE ADVERSE EFFECTS
CN111741753A (en) Method for treating hypertriglyceridemia
JP7257091B2 (en) Dementia treatment and preventive drug
JP2003501385A (en) Anti-hyperlipidemic combination comprising HMG-COA reductase inhibitor and carnitines
CN101534825A (en) Drug formulation containing fibrate medicament and process for producing the same
Palmer et al. Triethanolamine Trinitrate—Clinical Trial

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18827577

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18827577

Country of ref document: EP

Kind code of ref document: A1